City of Hope Initiates Phase 1b Clinical Trial of Elzonris and Azacitidine Maintenance Therapy for AML and MDS Patients
A New Challenge in Preventing Post-Transplant Relapse
City of Hope Medical Center, a leading cancer research institution in the United States, has officially launched a Phase 1b clinical trial to evaluate a novel combination maintenance therapy for high-risk Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) patients who have undergone Allogeneic Hematopoietic Cell Transplantation (HCT). This study aims to assess the safety and efficacy of combining Elzonris (tagraxofusp-erzs), an antibody-drug conjugate targeting the CD123 protein on cancer cells, with azacitidine (Vidaza), a hypomethylating agent (HMA). While hematopoietic stem cell transplantation offers a chance for cure, the risk of post-transplant relapse remains as high as 50%, making management during this period a critical determinant of long-term survival. This trial is considered an attempt to revolutionize the standard of care (SoC) for post-transplant treatment by providing personalized precision medicine solutions for patients at high risk of relapse.
CD123 Targeting Mechanism and Epigenetic Synergy
The key drug in the trial, Elzonris, uniquely binds to CD123 (Interleukin-3 Receptor Alpha Chain) and releases diphtheria toxin into cells, leading to cancer cell death. CD123 is highly expressed on AML stem cells and progenitor cells but is minimally expressed on normal hematopoietic cells, making it an ideal therapeutic target. The combination with azacitidine, an epigenetic modulator, aims to synergistically inhibit the proliferation of abnormal cells in the bone marrow and induce normal blood cell differentiation. Azacitidine induces gene demethylation, reactivating suppressed anti-cancer genes, and creates a bone marrow environment where Elzonris can precisely target CD123-positive cells, effectively controlling measurable residual disease (MRD).
Addressing Unmet Needs in the Post-Transplant Maintenance Therapy Market
Currently, approved standard maintenance therapies for patients at high risk of relapse after hematopoietic stem cell transplantation are extremely limited, resulting in significant unmet needs in clinical practice. Although Onureg, an oral azacitidine from Bristol Myers Squibb (BMY), has been approved for maintenance therapy in patients who have not undergone transplantation, there is a lack of established standard treatments for high-risk patients who have completed transplantation, highlighting the urgent need for alternative relapse prevention strategies. In particular, patients with CD123-positive expression have poor prognoses and exhibit resistance to conventional chemotherapy, making the establishment of targeted maintenance therapy crucial for extending survival.
Intensifying Competition in the CD123 Targeted Therapy Landscape
Currently, the CD123 targeted market is led by Elzonris, from Stemline Therapeutics (a subsidiary of Menarini Group), which received its first FDA approval in December 2018. However, strong competitors, such as Pivekimab Sunirine (PVEK), an antibody-drug conjugate (ADC) co-developed by Genmab and AbbVie (ABBV), are rapidly catching up. Furthermore, various modalities of therapeutic agents, including Flotetuzumab, a bispecific T-cell engager (BiTE) from MacroGenics, are competing in clinical trials. Amidst this intensifying CD123 target competition, Elzonris is strategically positioning itself to secure a unique niche market in post-hematopoietic stem cell transplantation maintenance therapy, aiming to expand its market share and strengthen its market dominance.
Clinical Roadmap and Global Market Impact
The initiated Phase 1b trial will enroll 43 patients and focus on confirming the drug's safety and establishing the recommended Phase 2 dose (RP2D). The first patient was dosed in January 2025, and the anticipated completion date for the primary endpoint is April 2027, suggesting that the long-term outcomes of the treatment will become apparent. Given that the global acute myeloid leukemia (AML) market is currently valued at approximately $4.8 billion in 2026 and is expected to maintain a robust annual growth rate of 10%, the success of this trial will undoubtedly be a critical turning point in expanding Elzonris's indications and increasing its revenue. By pioneering the unchartered territory of post-transplant maintenance therapy, this trial promises to offer hope for prolonged survival to patients and the potential for a highly profitable market to investors, marking a significant milestone.
This trial represents a strategic effort to secure a foothold in the 'post-transplant maintenance therapy' segment, an unaddressed area within the global acute myeloid leukemia (AML) market, currently valued at approximately $4.8 billion in 2026. By leveraging Elzonris's position as the first FDA-approved CD123-targeted therapy from Stemline Therapeutics (a subsidiary of Menarini Group), the trial aims to expand its indications to the post-transplant setting, which holds significant long-term commercial value. Amidst intensifying competition from CD123-targeted therapies such as Pivekimab Sunirine from Genmab and AbbVie (ABBV), the Phase 1b trial data, which seeks to reduce the 50% relapse rate observed in transplant patients, will be a key determinant of its future market dominance. Researchers anticipate that this trial will elucidate the mechanism by which the combination of CD123-targeted antibody-drug conjugates and azacitidine inhibits post-transplant measurable residual disease (MRD) and establish a new standard of care. Ultimately, the success of this trial will not only transform the treatment paradigm for high-risk hematologic malignancies but also accelerate the annual revenue growth of Elzonris.
Source: ClinicalTrials.gov (api_ct)